BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient’s T ...

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Allogenica SAS has been awarded a €2.5 million (US$2.7 million) grant under the French government’s France 2030 program to ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...